125 related articles for article (PubMed ID: 34118373)
41. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Yawn BP; Buchanan GR; Afenyi-Annan AN; Ballas SK; Hassell KL; James AH; Jordan L; Lanzkron SM; Lottenberg R; Savage WJ; Tanabe PJ; Ware RE; Murad MH; Goldsmith JC; Ortiz E; Fulwood R; Horton A; John-Sowah J
JAMA; 2014 Sep; 312(10):1033-48. PubMed ID: 25203083
[TBL] [Abstract][Full Text] [Related]
42. Integrative holistic approaches for children, adolescents, and young adults with sickle cell disease: A single center experience.
Mahmood LA; Thaniel L; Martin B; Marguiles S; Reece-Stremtan S; Idiokitas R; Bettini E; Hardy SJ; Cohen I; Connolly M; Darbari DS
Complement Ther Med; 2021 Aug; 60():102680. PubMed ID: 33601015
[TBL] [Abstract][Full Text] [Related]
43. Psychosocial and pharmacological management of pain in pediatric sickle cell disease.
Hildenbrand AK; Nicholls EG; Daly BP; Marsac ML; Tarazi R; Deepti R
Postgrad Med; 2014 Mar; 126(2):123-33. PubMed ID: 24685976
[TBL] [Abstract][Full Text] [Related]
44. Acupuncture and blood studies in sickle-cell anemia.
Sodipo J
Am J Chin Med; 1993; 21(1):85-9. PubMed ID: 8328427
[TBL] [Abstract][Full Text] [Related]
45. Association of Guideline-Adherent Antibiotic Treatment With Readmission of Children With Sickle Cell Disease Hospitalized With Acute Chest Syndrome.
Bundy DG; Richardson TE; Hall M; Raphael JL; Brousseau DC; Arnold SD; Kalpatthi RV; Ellison AM; Oyeku SO; Shah SS
JAMA Pediatr; 2017 Nov; 171(11):1090-1099. PubMed ID: 28892533
[TBL] [Abstract][Full Text] [Related]
46. Sickle Cell Disease: Considerations for Acute Pain Management in the Hematology-Oncology Ambulatory Setting.
Pohl E
Clin J Oncol Nurs; 2021 Oct; 25(5):605-607. PubMed ID: 34533511
[TBL] [Abstract][Full Text] [Related]
47. Validation of the sickle cell disease pain burden interview-youth.
Zempsky WT; O'Hara EA; Santanelli JP; Palermo TM; New T; Smith-Whitley K; Casella JF
J Pain; 2013 Sep; 14(9):975-82. PubMed ID: 23701707
[TBL] [Abstract][Full Text] [Related]
48. Acupuncture for Pain Management in Pediatric Patients with Sickle Cell Disease.
Plonski KS
Children (Basel); 2022 Jul; 9(7):. PubMed ID: 35884060
[TBL] [Abstract][Full Text] [Related]
49. Magnesium for treating sickle cell disease.
Than NN; Soe HHK; Palaniappan SK; Abas AB; De Franceschi L
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011358. PubMed ID: 28409830
[TBL] [Abstract][Full Text] [Related]
50. Patient characteristics affect the response to ketamine and opioids during the treatment of vaso-occlusive episode-related pain in sickle cell disease.
Nobrega R; Sheehy KA; Lippold C; Rice AL; Finkel JC; Quezado ZMN
Pediatr Res; 2018 Feb; 83(2):445-454. PubMed ID: 28902183
[TBL] [Abstract][Full Text] [Related]
51. Comparison of Parenteral Opioid Dosing in Adult Sickle Cell Disease Patients With Vaso-occlusive Crisis.
Shah SP; Twilla JD; Kemp L; Phelps GL; Reaves A
J Pain Palliat Care Pharmacother; 2018 Dec; 32(4):201-207. PubMed ID: 30896312
[TBL] [Abstract][Full Text] [Related]
52. Clinically meaningful measurement of pain in children with sickle cell disease.
Myrvik MP; Brandow AM; Drendel AL; Yan K; Hoffmann RG; Panepinto JA
Pediatr Blood Cancer; 2013 Oct; 60(10):1689-95. PubMed ID: 23776145
[TBL] [Abstract][Full Text] [Related]
53. Acute kidney injury during a pediatric sickle cell vaso-occlusive pain crisis.
Baddam S; Aban I; Hilliard L; Howard T; Askenazi D; Lebensburger JD
Pediatr Nephrol; 2017 Aug; 32(8):1451-1456. PubMed ID: 28238158
[TBL] [Abstract][Full Text] [Related]
54. Pain management in children and adolescents with sickle cell disease.
Jerrell JM; Tripathi A; Stallworth JR
Am J Hematol; 2011 Jan; 86(1):82-4. PubMed ID: 20949441
[TBL] [Abstract][Full Text] [Related]
55. The association between timely opioid administration and hospitalization in children with sickle cell disease presenting to the emergency department in acute pain.
Muslu CS; Kopetsky M; Nimmer M; Visotcky A; Fraser R; Brousseau DC
Pediatr Blood Cancer; 2020 Sep; 67(9):e28268. PubMed ID: 32614150
[TBL] [Abstract][Full Text] [Related]
56. Development and validation of the Youth Acute Pain Functional Ability Questionnaire (YAPFAQ).
Zempsky WT; O'Hara EA; Santanelli JP; New T; Smith-Whitley K; Casella J; Palermo TM
J Pain; 2014 Dec; 15(12):1319-27. PubMed ID: 25277425
[TBL] [Abstract][Full Text] [Related]
57. An innovative short-stay health care model for treatment of uncomplicated vaso-occlusive crisis in adult sickle cell disease patients in Canada to reduce emergency department utilization.
Binding A; Ward R; Phua C; Naessens V; O'Brien T; Bhatia S; Baranek H; Marani H; Mukerji G
CJEM; 2019 Jan; 21(1):55-62. PubMed ID: 29039292
[TBL] [Abstract][Full Text] [Related]
58. Positive expiratory pressure device acceptance by hospitalized children with sickle cell disease is comparable to incentive spirometry.
Hsu LL; Batts BK; Rau JL
Respir Care; 2005 May; 50(5):624-7. PubMed ID: 15871756
[TBL] [Abstract][Full Text] [Related]
59. Pediatric Sickle Cell Disease and Parent and Child Catastrophizing.
Sil S; Dampier C; Cohen LL
J Pain; 2016 Sep; 17(9):963-71. PubMed ID: 27263990
[TBL] [Abstract][Full Text] [Related]
60. Descriptive analysis of sickle cell patients living in France: The PHEDRE cross-sectional study.
Gerardin M; Rousselet M; Couec ML; Masseau A; Guerlais M; Authier N; Deheul S; Roussin A; Micallef J; Djezzar S; ; Feuillet F; Jolliet P; Victorri-Vigneau C
PLoS One; 2021; 16(3):e0248649. PubMed ID: 33735176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
